Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.

Cazelles, Clarisse;Belhadj, Karim;Vellemans, Hélène;Camus, Vincent;Haioun, Corinne;et.al.
(2021) Leukemia and Lymphoma — Vol. 62, n° 9, p. 2161-2168 (2021)

Files

CazellesCLeukLymphoma2021.pdf
  • Open Access
  • Adobe PDF
  • 1.41 MB
Download

Details

Authors
  • Cazelles, Clarisse
    Author
  • Belhadj, Karim
    Author
  • Vellemans, HélèneUCLouvain
    Author
  • Camus, Vincent
    Author
  • Haioun, Corinne
    Author
Show more
Abstract
There is no established standard treatment for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in patients who are not eligible to receive an intensive treatment. The combination of rituximab gemcitabine and oxaliplatin (R-GemOx) is widely used in this population but data are scarce. We retrospectively collected the data of 196 patients with R/R DLBCL treated with R-GemOx in two French centers over a period of 15 years. The median age of the population was 72 years (range, 24-89), 63% of the patients had an international prognostic index of 3 or higher and 57% were refractory to the last treatment. At the end of R-GemOx treatment, 33% of the patients obtained a complete response. The median progression-free survival (PFS) of the population was 5 months and the median overall survival (OS) was 10 months. Several factors were predictors of unfavorable survival: age over 75 years, international prognostic index of 2 or higher, refractory disease and de novo DLBCL. The median PFS and OS of the patients who obtained a complete response were 22 months and 40 months, respectively. The most significant toxicities were grade 3-4 hematological toxicities (31% of patients). Given its efficacy and tolerability, R-GemOx can be used in patients ineligible for intensive treatment and serve as a basis for new regimen combinations.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Cazelles, C., Belhadj, K., Vellemans, H., Camus, V., Poullot, E., Gaulard, P., Veresezan, L., Itti, E., Becker, S., Carvalho, M., Dupuis, J., Le Bras, F., Lemonnier, F., Roulin, L., El Gnaoui, T., Jardin, F., Mounier, N., Tilly, H., & Haioun, C. (2021). Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leukemia and Lymphoma, 62(9), 2161-2168. https://doi.org/10.1080/10428194.2021.1901090 (Original work published 2021)